Vimarsana
Biggest News Aggregation in the World

Page 20 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

Hepzato Kit Approved for Unresectable Hepatic-Dominant Metastatic Uveal Melanoma - Vimarsana News

Hepzato Kit Approved for Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

The Hepzato Kit (melphalan/hepatic delivery system) is approved as a liver-directed treatment for adults with metastatic uveal melanoma and unresectable hepatic metastases.

Unlocking the Benefits of FDA's Orphan Drug Designation - Vimarsana News

Unlocking the Benefits of FDA's Orphan Drug Designation

Securing an orphan drug designation is no small feat, in part because the number of patients affected cannot exceed 200,000 in the United States, despite population growth over 40 years.

Source: ajmc.com
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer - Vimarsana News

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in...

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma - Vimarsana News

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

Source: ajmc.com
Final EOM List Favors Larger Practices; AON Strategy Helps Smaller Groups - Vimarsana News

Final EOM List Favors Larger Practices; AON Strategy Helps Smaller Groups

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Source: ajmc.com